ISRCTN ISRCTN79422566
DOI https://doi.org/10.1186/ISRCTN79422566
Protocol serial number Protocol/Serial No: MI93
Sponsor NHS Greater Glasgow and Clyde (UK)
Funder Chief Scientist Office (UK) - Scottish Government (CZG/2/512)
Submission date
25/01/2013
Registration date
06/03/2013
Last edited
01/03/2019
Recruitment status
No longer recruiting
Overall study status
Completed
Condition category
Cancer
Prospectively registered
Protocol
Statistical analysis plan
Results
Individual participant data

Plain English summary of protocol

http://www.cancerresearchuk.org/cancer-help/trials/a-study-comparing-two-different-types-central-lines-people-due-start-course-chemotherapy

Contact information

Prof Jonathan Moss
Scientific

Dept of Radiology
Gartnavel General Hospital
1053 Great Western Road
Glasgow
G12 0DY
United Kingdom

Email jon.moss@ggc.scot.nhs.uk

Study information

Primary study designInterventional
Study designMulti-centre open randomised study
Secondary study designRandomised controlled trial
Study type Participant information sheet
Scientific titlePort-a-cath and Hickman line devices for chemotherapy delivery: A randomised phase II study and pre-trial economic model development to inform the design of a subsequent randomised phase III controlled trial
Study objectivesThe study hypothesis is that Ports are cost effective for the delivery of chemotherapy and that it is not appropriate to deny these devices to patients on grounds of purchasing costs alone. Although Ports are a little more difficult to insert and more expensive than Hickman lines, they carry potential advantages such as reduced infection and re-intervention rates, reduced maintenance and superior patient acceptability.
Ethics approval(s)West of Scotland REC 1, 05/04/2011, ref: 11/AL/0083
Health condition(s) or problem(s) studiedCancer, Chemotherapy, device study
InterventionPatients will be randomised in a 3:1 ratio to receive either a Hickman line (n=75) or a Port-a-cath (n=25).

Patients participating in the study will be asked to complete quality of life questionnaires (EQ-5D and device-specific) at baseline and subsequently monthly (sent out to the patients at home) during the insertion period; a further questionnaire will be completed at the time of planned line removal.

Patients will be seen as per standard of care for their treatment. Complication forms will be completed on a monthly basis by CTU Glasgow staff.
Intervention typeDevice
PhasePhase II
Drug / device / biological / vaccine name(s)
Primary outcome measure(s)

Cost effectiveness of Ports

Key secondary outcome measure(s)

Complication data including line infection (with and without antibiotics), tract infection, (with/without antibiotics), occlusion, migration, loss of line, central vein thrombosis, exit site haematoma, and skin breakdown will be recorded by clinical staff, on complication forms in case notes, as events occur and data collected by the clinical trial coordinator. Reinterventions including line replacement, thrombolysis, stripping and manipulations will be recorded by clinical staff, on complication forms in case notes, as events occur and data collected by the clinical trial coordinator.

Completion date01/07/2013

Eligibility

Participant type(s)Patient
Age groupAdult
Lower age limit18 Years
SexAll
Target sample size at registration100
Key inclusion criteria1. Oncology patients with solid tumours who are scheduled for access line insertion
2. Patients must be willing and clinically able to receive either a Hickman line or a Port-a-cath
3. Patient must provide informed consent
4. Age ≥18 years, male and female
5. Able to comply with study protocol
Key exclusion criteria1. Any evidence of any medical or psychiatric disorders that would be a contra indication to study participation
2. Life expectancy < 3 months
Date of first enrolment09/08/2011
Date of final enrolment01/07/2013

Locations

Countries of recruitment

  • United Kingdom
  • Scotland

Study participating centres

Gartnavel General Hospital
Dept of Radiology
1053 Great Western Road
Glasgow
G12 0DY
United Kingdom
Inverclyde Royal Hospital
Larkfield Road
Greenock
PA16 0XN
United Kingdom

Results and Publications

Individual participant data (IPD) Intention to shareYes
IPD sharing plan summaryAvailable on request
IPD sharing plan

Study outputs

Output type Details Date created Date added Peer reviewed? Patient-facing?
Results article results: 26/04/2016 Yes No
Participant information sheet Participant information sheet 11/11/2025 11/11/2025 No Yes

Editorial Notes

01/03/2019: Internal review.
04/08/2016: Verified study information with principal investigator. Added publication. Added data sharing plan. Added additional trial participant centre. Changed recruitment start date from 01/08/2011 to 09/08/2011. Changed recruitment end date from 31/07/2012 to 01/07/2013